Pancreatic neuroendocrine neoplasms: Updates on genomic changes in inherited tumour syndromes and sporadic tumours based on WHO classification.

Abstract

Pancreatic neuroendocrine neoplasms (PanNENs) are the neuroendocrine neoplasms with greatest rate of increase in incidence. Approximately 10% of PanNENs arise as inherited tumour syndromes which include multiple endocrine neoplasia type 1, multiple endocrine neoplasia type 4, von Hippel-Lindau syndrome, neurofibromatosis type1, tuberous sclerosis complex 1/2, Cowden syndrome, and Glucagon cell hyperplasia and neoplasia as well as familial insulinomatosis. In sporadic PanNENs, driver mutations in MEN1, DAXX/ATRX and mTOR pathway genes are associated with development and progression in pancreatic neuroendocrine tumours. The other changes are in VEGF pathway, Notch pathway, germline mutations in MUTYH, CHEK2, BRCA2, PHLDA3 as well as other genetic alterations. On the other hand, pancreatic neuroendocrine carcinomas share similar genetic alterations with ductal adenocarcinomas, e.g., TP53, RB1 or KRAS. In addition, microRNA and changes in immune microenvironment were noted in PanNENs. Updates on these genetic knowledges contribute to the development of management strategies for patients with PanNENs.

• Authors: Hirotaka Ishida, Alfred King-Yin Lam
• Journal: Critical reviews in oncology/hematology (Crit Rev Oncol Hematol) Vol. 172 Pg. 103648 (Apr 2022) ISSN: 1879-0461 [Electronic] Netherlands
• PMID: 35248713 (Publication Type: Journal Article, Review)
• Copyright: Copyright © 2022 Elsevier B.V. All rights reserved.

Topics

• Genomics
• Humans
• Neuroendocrine Tumors (genetics, pathology)
• Pancreatic Neoplasms (genetics, pathology)
• Syndrome
• Tumor Microenvironment
• World Health Organization